Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.

[1]  Wolfhard Semmler,et al.  Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study , 2010, Clinical Cancer Research.

[2]  J. Chirgwin,et al.  Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment , 2009, PloS one.

[3]  U. Klar,et al.  Sagopilone Inhibits Breast Cancer Bone Metastasis and Bone Destruction Due to Simultaneous Inhibition of Both Tumor Growth and Bone Resorption , 2009, Clinical Cancer Research.

[4]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[5]  Wolfhard Semmler,et al.  Assessment of vascular remodeling under antiangiogenic therapy using DCE‐MRI and vessel size imaging , 2009, Journal of magnetic resonance imaging : JMRI.

[6]  E. Schwartz.  Antivascular Actions of Microtubule-Binding Drugs , 2009, Clinical Cancer Research.

[7]  T. Plesner,et al.  A physical mechanism for coupling bone resorption and formation in adult human bone. , 2008, The American journal of pathology.

[8]  Fabian Kiessling,et al.  Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. , 2008, Neoplasia.

[9]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[10]  S. Groshen,et al.  The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. , 2007, Cancer research.

[11]  Bradford A Moffat,et al.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. , 2007, Cancer research.

[12]  Fabian Kiessling,et al.  Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging , 2007, European Radiology.

[13]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[14]  J. Body.  Breast Cancer: Bisphosphonate Therapy for Metastatic Bone Disease , 2006, Clinical Cancer Research.

[15]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[16]  P. Ubezio,et al.  The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis , 2006, Clinical Cancer Research.

[17]  F. Kiessling,et al.  Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein , 2005, International journal of cancer.

[18]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[19]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[20]  A. Herneth,et al.  Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. , 2003, European journal of radiology.

[21]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[22]  M. Décorps,et al.  Vessel size imaging , 2001, Magnetic resonance in medicine.

[23]  M. Kumegawa,et al.  Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts , 2000, FEBS letters.

[24]  Philip Smith,et al.  Risk of complications from bone metastases in breast cancer. implications for management. , 2000, European journal of cancer.

[25]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[26]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[29]  R. Edelman,et al.  Magnetic resonance imaging (2) , 1993, The New England journal of medicine.

[30]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[31]  Paul A. Bottomley,et al.  19F magnetic resonance imaging , 1977 .